Putting the ‘HAT’ back on survival signalling
Decreased histone acetyltransferase activity and transcriptional dysfunction have been implicated in almost all neurodegenerative conditions. Increasing net histone acetyltransferase activity through inhibition of the histone deacetylases (HDACs) has been shown to be an effective strategy to delay o...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , |
| Format: | article |
| Published: |
2009
|
| Online Access: | http://hdl.handle.net/10725/6143 http://dx.doi.org/10.1517/13543780902810345 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.tandfonline.com/doi/abs/10.1517/13543780902810345 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Decreased histone acetyltransferase activity and transcriptional dysfunction have been implicated in almost all neurodegenerative conditions. Increasing net histone acetyltransferase activity through inhibition of the histone deacetylases (HDACs) has been shown to be an effective strategy to delay or halt progression of neurological disease in cellular and rodent models. These findings have provided firm rationale for Phase I and Phase II clinical trials of HDAC inhibitors in Huntington's disease, spinal muscular atrophy, and Freidreich's ataxia. In this review, we discuss the current findings and promise of HDAC inhibition as a strategy for treating neurological disorders. Despite the fact that HDAC inhibitors are in an advanced stage of development, we suggest other approaches to modulating HDAC function that may be less toxic and more efficacious than the canonical agents developed so far. |
|---|